-+ 0.00%
-+ 0.00%
-+ 0.00%

Aclaris Reports Positive Phase 1b Results for ATI-052 in Atopic Dermatitis, Asthma

PUBT·10/27/2026 10:02:37
Listen to the news
Aclaris Reports Positive Phase 1b Results for ATI-052 in Atopic Dermatitis, Asthma
  • Aclaris Therapeutics announced positive Phase 1b proof-of-concept results for ATI-052 in atopic dermatitis and asthma on Oct. 27, 2026.
  • Atopic dermatitis patients experienced rapid skin and itch improvements, with responses sustained in patients with available follow-up data.
  • A single dose rapidly reduced airway inflammation and improved lung function in asthma patients.
  • Both trials showed favorable tolerability, with no conjunctivitis or adverse events leading to study discontinuation.
  • Development will prioritize eosinophilic esophagitis, with a Phase 2b trial planned for early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270600PRIMZONEFULLFEED9853602) on October 27, 2026, and is solely responsible for the information contained therein.